Breaking News

CordenPharma Transfers Assets to Chemie Uetikon

By Kristin Brooks | February 21, 2014

Will focus on peptide synthesis, specialized ingredient capabilities

CordenPharma Switzerland LLC, an API manufacturing facility in Liestal, has transferred its Amino Acid Building Blocks product portfolio to CU Chemie Uetikon GmbH, based in Lahr, Germany. Following the transfer, CordenPharma will focus on growing its core peptide synthesis and specialized ingredient manufacturing capabilities, including carbohydrates and synthetic lipids.
CordenPharma identified Chemie Uetikon as an ideal partner for larger scale manufacturing of amino acid building blocks, and Chemie will take over the Amino Acid business and market them to clients globally. CordenPharma will continue to manufacture and market Pseudoproline Building Blocks using its technology.
Dr. Juerg Burger, CordenPharma Switzerland’s chief executive officer commented, “CordenPharma is developing as a company and peptides are a key area for three of its API manufacturing facilities — CordenPharma Switzerland, CordenPharma Colorado (Boulder, CO, USA) and Peptisyntha (Brussels, BE). We are excited to have Chemie Uetikon as an established and highly motivated supplier for the company.”
Thomas Seeler, Chemie Uetikon's chief financial officer and chief operating officer, said, "Uetikon has been a hidden champion of Amino Acid Building Block manufacturing up to now."
Dr. Stefan Peterli, chief executive officer at Chemie Uetikon added, "We are looking forward to serving customers globally with Amino Acid Building Blocks of non-animal, non-human grade, made in Germany."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks